Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

08 Nov 2024 05:35:00 By Nasdaq GlobeNewswire

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

04 Nov 2024 06:35:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

25 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in October

01 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

06 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in September

03 Sep 2024 07:32:32 By Nasdaq GlobeNewswire

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

12 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Y-mAbs to Participate in Upcoming Investor Conferences in August

07 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

05 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

01 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

07 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

05 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

01 Jun 2024 07:15:00 By Nasdaq GlobeNewswire

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

01 Jun 2024 07:05:00 By Nasdaq GlobeNewswire

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

07 May 2024 15:05:01 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

26 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Present at 2024 ASCO Annual Meeting

25 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

14 Mar 2024 08:05:00 By Nasdaq GlobeNewswire

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

04 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire